Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
ZURICH Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.
ZURICH Swiss hearing aid maker Sonova reported first-half results that fell short of analyst expectations, as sales in the United States were dented by an overhaul of the company's retail network there.
ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
ZURICH Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year.
ZURICH New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid efforts to muscle in on turf dominated by rival Pfizer's Ibrance.
ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion (2.99 billion pounds), giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.
ZURICH Clariant Chief Executive Hariolf Kottmann said it would be "premature" to do an outside strategy review, a key demand of activist shareholders who derailed the Swiss chemical maker's planned $20 billion merger with U.S.-based Huntsman .
ZURICH Clariant , the Swiss speciality chemicals maker whose top investor derailed its $20 billion merger with Huntsman , posted better-than-expected third-quarter sales and operating profit on Tuesday as acquisitions added to results.
ZURICH The fight over chemicals company Clariant's future turned bitter on Monday as activists who thwarted a $20 billion merger with Huntsman threatened to call a shareholder meeting if they do not get three board seats and a strategy review.
ZURICH Swiss speciality chemicals maker Clariant and U.S. group Huntsman abandoned their $20 billion(£15.28 billion) merger on Friday, notching a win for activist investors who fought the deal for months on the grounds it would destroy shareholder value. | Video